Novo Nordisk Stock
The trading unit of B shares listed on NASDAQ Copenhagen and American Depositary Receipts that equal the B-shares listed on NYSE have been split as of 13 September 2023.
Company Overview Novo Nordisk Stock
Danish pharmaceutical giant Novo Nordisk reports third-quarter earnings Wednesday morning, and investors will be looking to see whether sales of the company’s popular weight loss drugs Ozempic and Wegovy can continue to grow. Wall Street analysts are generally bullish on Novo Nordisk, and the stock has a consensus price target about 28% above current levels.
The company’s B shares are listed on NASDAQ Copenhagen, while American Depository Receipts (ADRs) that equal DKK 0.20 are listed on the New York Stock Exchange. The company’s A shares are held by the Novo Holdings A/S foundation, which is a public limited liability corporation with dual objective of providing a stable basis for the commercial and research activities of companies within the Group, as well as supporting scientific and humanitarian purposes.
Novo Nordisk’s business segments include novo nordisk stock Diabetes and Obesity Care, and Rare Disease. The former includes products for diabetes, obesity, cardiovascular and emerging therapy areas. The latter consists of rare blood disorders, rare endocrine disorders and hormone replacement therapy. In addition to its flagship drugs, the company also offers a variety of smart solutions for diabetes treatment. This includes insulin pens, growth hormone pens and injection needles, and an app that helps diabetics manage their condition better.
Novo Nordisk has a robust product pipeline, and is continuing to invest in new research and development projects. It also has a strong balance sheet, with enough cash to fund its dividend for more than 10 years. However, the company faces competition from generics and other newer treatments, as well as from rivals novo nordisk stock introducing their own versions of its popular drugs. Its liraglutide injectable formulation of its popular weight-loss drug Wegovy is already facing increased competition from a similar product from Amgen, and an upcoming competing product from Viking Therapeutics. These headwinds have weighed on the company’s share price, which has slumped since the beginning of 2024.
Financials Novo Nordisk Stock
The company’s share capital is divided into A shares and B shares. The A shares are not listed and are held by Novo Holdings A/S, a Danish public limited liability company wholly owned by the Novo Nordisk Foundation. The Foundation has a dual objective: to provide a stable basis for the commercial activities of the Novo Group and to support scientific and humanitarian purposes. The total number of A shares is 107,487,200 and the number of B shares is 343,512,800.
As of 13 September 2023, the novo nordisk stock trading unit of the B shares listed on NASDAQ Copenhagen has been changed from DKK 0.20 to DKK 0.10 and the ADRs on NYSE have been split in two to maintain a 1:1 relationship between the two. These changes have been implemented to align price levels of the B-shares and ADRs with market practice.
As a Novo Nordisk shareholder, you can access information about your personal shares and American Depository Receipts (ADRs) online. You can find historic share prices, calculate your return on investment and see how much the company has paid out in dividends. You can also manage your share registration and change your contact details. Novo Nordisk’s Investor Portal is designed to give shareholders all the tools they need to stay informed and take control of their investment.
Product Portfolio Novo Nordisk Stock
Novo Nordisk’s portfolio is diverse and includes both diabetes-care and biopharmaceutical products. Its diabetes care segment accounts for about one-third of the global branded diabetes treatment market. Its offerings include injectable insulin, GLP-1, glucagon and other protein-related products as well as oral anti-diabetic drugs. The biopharmaceutical segment includes the company’s Hemophilia care, growth hormone therapy and hormone replacement therapies, among others.
The company’s diversified product novo nordisk stock pipeline helps to ensure it can maintain its leadership in the diabetes and obesity markets and address other chronic diseases such as rare blood disorders, endocrine diseases and cardiovascular disease. Recent catalysts like the Food and Drug Administration’s expanded approval of its blockbuster weight loss drug Wegovy to reduce cardiovascular risks in overweight patients expands the pool of Medicare beneficiaries eligible for coverage and adds another revenue stream.
In addition to expanding its product portfolio, Novo Nordisk is also leveraging its partnerships to develop new technologies to enhance its existing products. For instance, the company has partnered with Korro Bio to develop genetic medicine to help improve insulin production.
As the healthcare sector continues to see robust growth driven by an ageing population, rising healthcare spending and advancements in biotech and other pharmaceuticals, companies that can adapt to changing market conditions will be positioned to benefit. Novo Nordisk’s comprehensive portfolio, strategic partnerships and commitment to innovation position the company to thrive in a shifting market environment.
With offices and production novo nordisk stock facilities in more than nine countries, Novo Nordisk’s reach extends worldwide. The company has two main divisions: Diabetes and Obesity Care and Rare Disease, both dedicated to curating products tailored towards diabetic management, obesity treatment and other chronic diseases. This holistic approach to health underscores the company’s mission to drive change and improve people’s lives. In addition to providing information on the company’s history, earnings and dividends, this page contains tools for investors and shareholders, including a historic share price chart, calculators and the ability to view stock quotes and American Depository Receipts (ADRs). It is updated frequently to reflect the most current financial data available. It’s an easy way to stay informed about your investment in this global powerhouse.
Dividends Novo Nordisk Stock
Whether you’re an existing shareholder or considering purchasing Novo Nordisk stock, the company’s dividend history provides valuable insight. This chart shows Novo Nordisk’s historical quarterly dividend per share, as well as the ex-dividend date and payment date. It also includes the average yield, which is the annualized amount of a stock’s current quarterly dividend divided by its share price.
The chart also displays the company’s 5-Year Dividend Growth Rate. This indicates how quickly the company has been increasing its dividend payments over the past five years.
Novo Nordisk A/S is a healthcare company that manufactures and markets pharmaceutical products. The Company’s segments include Diabetes and Obesity Care, Cardiovascular Disease, Emerging Therapy Areas, and Rare Disease. The Company’s products are sold worldwide. Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
During the quarter ending in Sep. 2024, Novo Nordisk A/S paid a dividend of $0.51 per share. Its B shares are listed on NASDAQ Copenhagen in trading units of DKK 0.20, and its American Depositary Receipts (ADRs) that equal the B-shares have been listed on the New York Stock Exchange in units of $1.00.
Investors can use the Investor Portal to track their Novo Nordisk stock, calculate their return on investment and see their share price history. They can also access the latest dividend information, track the company’s share capital history and see the number of analysts covering the stock.
More Words
The Novo Nordisk dividend yield is 1.35%. This is novo nordisk stock higher than the dividend yield of 2.4% and the median dividend yield of 1.00%. It’s also significantly higher than the yield of other large healthcare stocks like Eli Lilly and Viking Therapeutics, which are trading at around 1.5% dividend yield.
Novo Nordisk’s third-quarter sales fell short of estimates despite continued growth from weight loss drugs Ozempic and Wegovy. The company also narrowed its full-year projections for revenue and operating profit. In the premarket, shares fell as much as 2.8%.
